Ipsen
LeaveRussia detail: Scaling Back
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world’s top 15 biopharmaceutical companies in terms of oncology sales.
Decision trail
Decision date 04/03/2022 · Reference ↗
Continues serving patients. March 29, 2022 "In line with our relentless commitment to serving patients, we will continue to tackle their healthcare needs regardless of their race, sex, nationality, ethnicity, country of origin, language, or religion. We support global sanctions, and we will take all precautionary measures to comply with them. We have suspended several promotional activities in Russia, including advertising and participation to non-scientific congresses. Additionally, we will not initiate any new clinical trials." Revenue decreased in 2024 vs 2023 by more than -10%.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — scaling back · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional